Periprocedural and postprocedural anticoagulation during arterial reconstructive surgery (ARS) with intravenous heparin is standard of care. The general use and correct dosage of low-molecular-weight heparin, however, are still under debate. A prospective, randomized, double-blind trial was performed with a parallel group comparison of four dose regimen of a low-molecular-weight heparin, reviparin sodium, in patients undergoing major ARS. Sixty-five patients were randomly allocated to receive twice-daily subcutaneous injections of reviparin, 3500 (group A, n=17), 4200 (group B, n= 16), 5950 (group C, n= 16), and 7000 (group D, n= 16) anti-Xa IU per day. Patients were eligible for the trial if they had angiographically proven peripheral arterial obstructive disease with a planned arterial reconstruction of the infrarenal aorta, iliaca artery, or femoralis artery. Fifty-nine patients completed the trial. The goal was to determine the optimal dose of the low-molecular-weight heparin to achieve a minimum of early vascular events (less than 12%) with a minimum of major bleeding events (less than 10%) during a shortterm follow-up of up to 8 postoperative days. There was no reocclusion in the entire population. Patients randomized into the two lower dose groups (A and B) , however, experienced a relatively high incidence of restenosis, whereas patients enrolled in group D, receiving the highest dose of reviparin, experienced an unacceptably high rate of bleeding events (all bleeds, 43%; major bleeding, 14.3%). Thus, the optimal dose of reviparin sodium to be administered in patients undergoing major ARS is half the therapeutic dose: 5950 to 6300 anti Xa IU (75-85 anti Xa IU/kg body weight per day). Patients included in group C had no major bleeding event (95% confidence interval, 0% to 6.6%), a significant improvement of the doppler anklebrachial systolic pressure index (difference of 0.46 + 0.29, P=.017), and a higher rate of responders with regard to the puls status measured at the tibialis posterior arteries (66.7%) compared to groups A and B (46.7% and 54.5%, respectively, P=.086). The efficacy and safety of this dosage regimen in comparison to standard of care should be further substantiated in larger trials.
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Knowledge of the best pharmacologic means of preventing thrombotic complications of infrarenal vascular surgery is limited. The aim is to prevent, with little risk of adverse events for the patient, graft occlusion and thrombus formation in the clamped vessel during and after the operation, especially in the early months after surgery. Treatment should also prevent postoperative venous thromboembolism. Since the first use of heparin during vascular reconstruction in 1940, most surgeons have routinely recommended heparin during and after arterial surgery. Administration of a fixed or bodyweight-dependent dose of unfractionated heparin during major arterial reconstructive surgery has become widely accepted for the prevention of intravascular thrombosis (1, 2) . Lowmolecular-weight heparin may offer an interesting alternative to unfractionated heparin, because of its higher bioavailability, prolonged halflife, and a higher antithrombotic activity associated with a lower incidence of bleeding complications (3) (4) (5) (6) (7) (8) (9) (10) (11) . Some other properties of low-molecular-weight heparin, a lower incidence of heparin-induced thrombocytopenia (12, 13) and a lower incidence of myointimal hyperplasia (14) (15) (16) , need to be confirmed by further trials. There are little data available concerning the dose of low-molecular-weight heparin recom-mended during and after major arterial reconstructive surgery (4, 6, 7, 11) . The aim of this study was to determine the optimal dose of lowmolecular-weight heparin, reviparin sodium, during proximal arterial surgery.
METHODS

Study Design
This prospective, randomized, double-blind, parallel-group, dose-finding trial with four dose groups was conducted in the University Hospital Lilbeck, Department of Surgery (Liibeck, Germany) between March 1996 and March 1998. The study was approved by the Institutional Ethics Committee on January 25, 1996, and was performed in accordance with the declaration of Helsinki and good clinical practice.
Patients
Sixty-four patients older than 30 years were enrolled and randomized into the trial (safety population) to ensure a number of 48 evaluable patients. Patients are eligible for the trial if they have angiographically proven peripheral arterial obstructive disease (PAOD) (Fontaine IIb, III, or IV) and are scheduled for proximal arterial reconstructive surgery of the infrarenal aorta, iliaca artery, and femoralis artery. Patients were excluded if they were pregnant, had a thrombophilic or hemorrhagic diathesis, recent major trauma, hemorrhagic stroke, intracranial bleed, other conditions indicative for vascular lesions and increased risk of bleeding, severe untreated hypertension (diastolic > 105 mmHg), severe renal or liver insufficiency (creatinine >240 mmol/L; prothrombin time < 70%, liver transaminase levels > 100 U/L), and generally other severe concomittant diseases. All patients gave written informed consent to participate in this trial.
Medication
Low-molecular-weight heparin: Prefilled syringes containing 0.6 mL injection solution with different doses of reviparin sodium (Clivarin®, Knoll GmbH, Ludwigshafen, Germany). Reviparin is prepared by chemical cleavage of porcine mucosal heparin with nitrous acid and further purified.
Treatment Regimens
Patients were randomly allocated to one of the four trial groups, receiving different dosages of reviparin sodium: group A, 3500 anti-Xa IU; group B, 4200 anti-Xa IU; group C, 5950 anti-Xa IU; and group D, 7000 anti-Xa IU. Trial medication was blinded by a double-dummy technique and administered in prefilled syringes containing 0.6 mL injection solution. Each patient was received two subcutaneous injections per day: group A, 1750 anti-Xa IU twice daily; group B, 4200 anti-Xa IU once daily plus matching placebo (0.6 mL saline); group C, 1750 anti-Xa IU in the morning and 4200 anti-Xa IU in the evening; group D, 3500 anti-Xa IU twice daily. The first dose of trial medication was given on the day before surgery, the second dose 2 to 4 hours preoperatively. Planned duration of treatment was 9 to 10 days (i.e., 7-8 postoperative days).
Surgical Intervention
The surgical procedure in the reconstruction of the infrarenal aorta and the iliaco-femoral arteries is standardized according to the approaches outlined by VOLLMAR. Five minutes before clamping of the aorta 5000 IU unfractionated heparin were administered intravenously. Additional applications of heparin during the operation (especially as an additive to a 0.9% saline solution) were not done. The reconstruction of the aorta and iliac vessels was performed with dacron-velour prothesis (GoreTex). Suture material was acrylic polyamide (Prolene 4-0, central anastomosis; 5-0, distal anastomosis). Polytetrafluoroethylene grafts were used as bypass material. In cases of thrombendarterectomy, reconstruction was performed with dacron patches. Before the anastomosis was completed, a flash manuver was performed and the bypass was rinsed with saline solution. All patients with reconstruction of the aorta were monitored in the intensive care unit for 1 day; other patients in the intermediate care unit also for 1 day.
Endpoints
The aim of this trial was to determine the optimal dose of reviparin both with regard to efficacy (restenosis, re-occlusion) as well as to tolerability (major bleeding events). The minimally effective dose of reviparin sodium should ensure a maximal rate of re-occlusions less than 12%. An early re-occlusion is defined as positive clinical symptom(s) of occlusion, and a non-measurable ankle systolic pressure (<50 mmHg) using doppler-sonography, and a localization within the reconstructed vessel area. Besides complete re-occlusions, a worsening or a lack of improvement of puls status/doppler ultrasonographic determination of the ankle-brachial and toe-brachial systolic pressure index of the reconstructed site was also taken into consideration as a secondary efficacy parameter. The maximal tolerable dose of reviparin sodium should not exceed an incidence of major bleeding events of 10%. All intracranial, retroperitoneal, intraocular, clinically overt bleeding events, as well as those requiring cessation of medication, or transfusion of more than 2 U of blood are considered major events.
Assessment of Outcome
Clinical follow-up was done on a day-to-day basis. Doppler ultrasonographic examination, and determination of the ankle-brachial systolic pressure index (ABI) were performed preoperatively and on days 5 to 7 and on the day before discharge. On days 3 to 4 and 7 to 9, the ultrasonographic determination of systolic pressure was performed in the posterior tibial artery or the dorsalis pedis artery using a sphygmomanometer with the cuff positioned proximal to the malleoli and a doppler ultrasound probe. The pulse was located with the doppler probe, and the cuff inflated until the pulse was obliterated; the cuff was then deflated and the pressure recorded at the point when the pulse reappeared.
Sample Size Considerations
Considering a minimal difference of the incidence of re-occlusions among the groups of 0.1, the sample size should be sufficient to increase the theoretical probability of choosing the right dose from 0.25 to 0.45. This quality was considered sufficient for this pilot trial and led to 12 evaluable patients per group.
Statistical Analysis
The aim was to determine the "optimal," that is, minimally effective and maximal tolerable dose of reviparin to prevent early re-occlusions. However, only those doses would be considered sufficient that would decrease the re-occlusion rate below 12%, and would in the same time not result in a greater than 10% incidence of major bleeding events. All other parameters and variables were analyzed with descriptive, explorative statistics.
RESULTS
Baseline Characteristics
Sixty-five patients (44 males and 21 females) at a mean age of 62.4 + 10.6 years were enrolled into this trial between March 1996 and March 1998. All patients underwent peripheral arterial occlusive disease requiring proximal arterial reconstructive surgery. Forty-two patients were classified as stage Fontaine Ilb; 10 and 11 patients belonged to stages Fontaine III and IV, respectively. The severity of their disabling PAOD lasting for 2.2 years was evidenced by a high number of patients with ulcerations (n= 6), gangrene (n=9), and a pain-free walking distance below 50 m (n=41; 63%). Patients were randomly allocated to one of four parallel dose groups (A-D), which were well matched with regard to their baseline characteristics and demographic data ( Table 1) .
Preoperative status of PAOD was further characterized by clinical investigations, doppler-sonographic determination of the ankle-brachial, and toe-brachial systolic pressure index, as well as by angiography ( Table 2) . Two thirds of all patients had a complete or near-complete arterial occlusion; one third a 90% to 95% stenosis of the target vessel. Most of the patients had short stenosis (<5 cm, 62%). The most severe puls status at the site of surgery was classified as "no doppler signal" in 65.6% and as "not palpable, but doppler signal" in 26.6% of the patients. Preoperative ankle-brachial systolic pressure index determined by doppler sonography was 0.44 + 0.31, indicating severe PAOD requiring surgical intervention. Two patients, one in each of groups A and C, had an aortic aneurysm.
Fifty-nine patients underwent surgery, 38 thrombendarterectomy (TEA) (64.4%), six TEA plus bypass (10.2%), eight bypasses, four TEA plus patch, two resection of an aneurysm, and one PTA ( Table 3 ). All but one patient had inhalative anaesthesia lasting for 3.7 ± 1.1 hours. The incision-suture time was 2.9 ± 1.1 hours; one third of all patients had to have intraoperative transfusion.
Efficacy
There was no complete re-occlusion during the postoperative follow-up period of 8 days. The corresponding 95% confidence interval for 0% re-occlusion in 54 completely documented patients is 0.0% to 6.6%; hence, well within the a priori defined maximum of 12%. Improvement of clinical puls status of femoralis arteries, popliteal arteries, tibialis posterior arteries, and dorsalis pedis arteries was evaluated. The more distal vessels were more indicative when comparing puls status before/after surgery. The responder rate (clinically relevant improvement of . There was also a dose-dependent improvement of the maximal walking distance, and the pain-free walking distance (100% responders in dose groups C and D; Table 4 ).
Safety
There was an 8.5% rate of major bleeding events in the entire study population. The highest dose of reviparin (group D) was associated with 14.3% of major bleeding events, well above the a priori set 10% limit. Group C receiving approximately 6000 anti-Xa IU per day, in contrast, did not experience a single major bleeding event. Group C was also the group with the lowest Data given as mean ± SD. ABI = ankle-brachial (or toe-brachial) systolic pressure index determined by Doppler sonography. transfusion requirements (none; compared to five in group D), and the lowest number of patients with postoperative bleeding events (two; compared to six in group D) ( Table 5 ).
There were no relevant changes in hematologic or other laboratory parameters. No single case of heparin-induced thrombocytopenia was observed.
DISCUSSION
Results of arterial reconstructive surgery (ARS) in iliac or femoral arteries mainly depend on two parameters: quality of the surgical intervention, and the peripheral flow/resistance (17) (18) (19) (20) . For that reason, the arterial reconstruction of the iliac and femoral arteries was choosen tF-test for a difference between groups (intent-to-treat population).
TF-test for a difference between groups (per protocol population). as a model to perform assessment of dose of lowmolecular-weight heparin, to eliminate other factors, such as peripheral resistance, which might influence the outcome. Anticoagulation is considered another important factor that influences the incidence of early or late re-occlusions after ARS. Alloplastic material, frequently used in ARS, is highly thrombogenic and may therefore increase the rate of postoperative reocclusions. Hence, anticoagulation is a prerequisite in reconstructive vascular surgery. Unfractionated heparin has been used for years (1) in this indication despite the fact that well-designed dose-finding trials are lacking. Moreover, unfractionated heparin (UFH) does have a number of disadvantages compared to low-molecular-weight heparins: UFH has to be administered intravenously, requires frequent monitoring of the activated partial thromboplastin time, is associated with a high binding to plasma proteins, and causes more frequent heparin-induced thrombocytopenia (HIT type II) (12, 13) . Potential advantages of low-molecular-weight heparins over unfractionated heparins are no need for monitoring, higher bioavailability, subcutaneous administration, less activation of platelets (21) , and, generally, a broader therapeutic index. For that reason, the present study was performed to define the optimal dose of a low-molecular-weight heparin, reviparin, in ARS. Reviparin was choosen because of its more specific method of fractionation leading to a second-generation low-molecular-weight heparin characterized by a narrow molecular weight distribution. It has been shown to be particularly safe in other clinical investigations using high doses in arterial interventions, such as PTCA14, 15, or PTA22. Moreover, animal studies revealed a pronounced effect of reviparin on the inhibition of smooth muscle cell proliferation after balloon angioplasty (14, 16) .
Previous trials with other low-molecularweight heparins in arterial reconstructive surgery used dosages from 20 to 120 anti-Xa IU/kg body weight. Alimi and associates (4) demonstrated a lack of efficacy for 20 to 40 anti-Xa IU/kg, whereas a dose of 120 anti-Xa IU/kg was associated with a markedly increased risk of bleeding in the same trial. Samama and McMillan successfully used higher dosages, 180 anti-Xa IU/kg or 85 anti-Xa IU/kg twice daily (3, (5) (6) (7) . Therefore, we decided to investigate four dose groups: 3500, 4200, 5950, and 7000 anti-Xa IU per day, corresponding to 50 to 100 anti-Xa IU/kg body weight, or half the therapeutic dose. One goal was to demonstrate at least the same efficacy as historically known for unfractionated heparin, but a better practicability, in other words, to omit the IV drip, and to mobilize the patients earlier.
Our results demonstrate that there was no reocclusion with the tested dosages, indicating that the efficacy of all tested dose regimens was fulfilling the minimal criteria we defined a priori. All four groups were comparable regarding their baseline characteristics (i.e., demographics, severity of disease, concomitant diseases, and medications). Our trial also specifically addressed the question of the frequently occurring co-medication with aspirin. Patients with lowdose aspirin were not generally excluded to increase practicability of the trial and to keep it generalizable. Moreover, data from recent studies (14) with reviparin showed that even high doses of 7000 anti-Xa IU reviparin per day did not increase the bleeding risk when given together with low-dose aspirin up to 325 mg. To avoid severe bleeding complications in this dosefinding trial, all patients with a clinically relevant prolongation of their bleeding time (23), these patients were excluded. The safety parameters clearly revealed a dose relationship: the highest dose tested clearly exceeded the a priori defined threshold of 10% major bleedings. Most of the major bleeding events occurred on the first postoperative day, indicating a need for a lower postoperative dose, with subsequent increase of the dose from the second postoperative day on.
With regard to other safety parameters, levels of antithrombin III and platelet count were closely monitored. Antithrombin, the cofactor of heparin, may decrease during systemic heparinization. Therefore, it was essential to monitor antithrombin levels to avoid insufficient anticoagulation. Irrespective of the dose administered, no relevant changes in the antithrombin levels were observed. Heparin, particularly unfractionated heparin, may cause heparin-induced thrombocytopenia (HIT), a potentially severe side effect. Atherosclerotic patients undergoing vascular surgery are particularly prone to develop heparin-induced platelet-factor 4 antibodies (13). Low-molecular-weight heparin has been shown to induce HIT less often compared to unfractionated heparin (12) , and to cause less platelet activation (21) .
Groups A and B in contrast showed inferior puls status and lower doppler pressure indices compared to groups C and D. A dose of approximately 6000 anti-Xa IU as administered in group C seems to be the optimal dose to be further substantiated in larger scale confirmatory trials.
Further trials have to address the efficacy and safety of low-molecular-weight heparin in patients undergoing arterial reconstructive surgery of the femoro-popliteal or even femoro-crural segments. CONCLUSION Low-molecular-weight heparin, reviparin, can safely be given during and after proximal arterial reconstructive surgery. The optimal daily dose with regard to both efficacy and safety should be half of the therapeutic dose, that is, 85 anti-Xa IU/kg body weight (5950-6300 anti-Xa IU). Patients allocated to the lower dose groups A and B experienced unfavorably high incidences of reocclusion/restenosis, whereas patients randomized to the highest dose (group D) had untolerable high incidence of major bleeding events. The optimal dose has now to be confirmed in larger randomized controlled trials versus unfractionated heparin.
